Actos Bladder Cancer Side Effects Lawsuit News Archive
Suspicious Behavior of Drug Manufacturers Lands them in Court
- Ennis & Ennis
05/08/2012 - In the case known as U.S. ex rel. Helen Ge v. Takeda Pharmaceutical Co. the maker of Actos is under fire for trying to influence the medical reviewers of the drug to “change their professional opinions” when reviewers found that there were heart problems associated with the use of Actos. Ge brought suit under the False Claims Act and claims Takeda tried to avoid letting the FDA know about the association with Actos and congestive heart failure.
READ MORE::
Actos Drug-Maker Fails to Obtain FDA Approval for New Diabetes Medication
- Ennis & Ennis
04/26/2012 - The U.S. Food and Drug Administration (FDA) delayed its approval on a new diabetes medication, alogliptin, requesting additional data from the manufacturers. Japan’s Takeda Pharmaceutical Co Ltd (Takeda) has been trying to obtain FDA approval for several years on what the company hopes will be the successor to its top-selling diabetes drug, Actos.
READ MORE::
Actos Manufacturer Warns of Actos Bladder Cancer Risk in Canada
- Ennis & Ennis
04/25/2012 - On April 16, 2012 Health Canada warned diabetes patients of the increased risk of developing bladder cancer associated with the diabetes drug, Actos (pioglitazone). Takeda Canada, the Canadian manufacturer of Actos, joined Health Canada in issuing the safety communication, confirming the link of Actos with bladder cancer.
READ MORE::
Health Canada warns diabetes drug Actos may pose bladder cancer risk
- Winnipeg Free Press
04/19/2012 - Taking the diabetes drug Actos may increase one's risk of developing bladder cancer, Health Canada and the drug's maker, Takeda Canada Inc., said in a warning issued Thursday. The statement was the culmination of a safety assessment Health Canada announced last June, two days after the U.S. Food and Drug administration issued a warning similar to the one the Canadian drug regulator just announced.
READ MORE::
Takeda Hid Actos Bladder Cancer Risks, Whistleblower Case Says
- Salient News
03/12/2012 - The U.S. District Judge F. Dennis Saylor issued an order to unseal a whistleblower case by a former Takeda Pharmaceuticals medical reviewer involving the failure to report bladder cancer and Congestive Heart Failure (CHF) adverse events for the diabetes drug Actos.
READ MORE::
Takeda Hid Actos Adverse Effects From Regulators, Suit Says
- Bloomberg
03/07/2012 - A U.S. unit of Takeda Pharmaceutical Co. failed to give accurate reports to regulators about hundreds of congestive heart failure cases associated with its diabetes drug Actos, a whistle-blower claimed in a lawsuit.
READ MORE::
Judge Schedules First Hearing for Federal Actos Bladder Cancer Lawsuits
- Ennis & Ennis
02/16/2012 - On Monday, Judge Rebecca Doherty scheduled an initial court hearing for March 22, 2012, wherein she will be appointing lead counsel to the consolidated Actos Bladder Cancer Lawsuits.
READ MORE::
Simple Math on Diabetes and Actos Bladder Cancer Dangers
- JD Supra
01/27/2012 - There have been numerous Actos lawsuits filed throughout the country. Due to the large and growing number of Actos claims, those claims filed in federal court have been consolidated to the Western District of Louisiana. Due to the large number of users of the drug, the number of legal claims is likely to grow exponentially in the coming months and years.
READ MORE::
Edwardsville man sues Takeda, Eli Lilly over Actos
- Madison Record
01/19/2012 - William R. Greenlee and his wife, Diana, filed a complaint Jan. 4 in Madison County Circuit Court against Takeda Pharmaceuticals America Inc., Takeda Pharmaceuticals North America Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company.
READ MORE::
Federal Actos Lawsuits Consolidated to Single Judge in Louisiana
- Ennis & Ennis
01/04/2012 - On December 28, 2011, the U.S. District Court for the Western District of Louisiana consented to the assignment of all federal Actos cases to Honorable Rebecca F. Doherty. As a result, more than 100 cases will be transferred to the Western District of Louisiana at this time. “I have no doubt this number will increase significantly because consumers are still learning of the link between Actos and bladder cancer,” commented attorney David Ennis of Ennis & Ennis, P.A.
READ MORE::
Takeda Actos Suits Combined in Louisiana Court, Panel Rules
- Bloomberg
01/02/2012 - Lawsuits against Takeda Pharmaceutical Co., Asia’s biggest drugmaker, claiming its Actos diabetes drug causes bladder cancer will be consolidated before one judge in federal court in Louisiana, a judicial panel said. The federal Judicial Panel on Multidistrict Litigation sent the lawsuits to the Western District of Louisiana, in Lafayette, to be overseen by U.S. District Judge Rebecca Doherty. Doherty will coordinate pretrial proceedings, including evidence- gathering.
READ MORE::
Diabetes drug class action launches: Suit alleges manufacturer should have disclosed increased bladder cancer risk
- CBC
12/22/2011 - A class action has been launched on behalf of people who took the diabetes drug Actos against the manufacturers of the medication. The class action alleges that Takeda Pharmaceutical Company, the manufacturer and distributor of Actos (pioglitazone hydrochloride) and Eli Lilly, who used to sell and distribute the drug, failed to disclose that taking it for longer than one year led to an increased risk of bladder cancer.
READ MORE::
Actos Lawsuits Continue to Increase While Attorneys Seek to Consolidate the Cases to One Judge
- Ennis & Ennis
12/09/2011 - Last week a judicial panel in Savannah, GA listened to the oral arguments for plaintiffs, who have pending lawsuits against Japanese company Takeda Pharmaceuticals America Inc. (Takeda), the manufacturer of the Type II diabetes drug, Actos, seeking to have all federal Actos claims consolidated and transferred to one presiding judge. The consolidation avoids document duplications and inconsistent rulings, while also potentially saving on expert testimony.
READ MORE::
Takeda May Face 10,000 U.S. Suits Over Actos Cancer Claims
- Diabetes.co.uk
12/05/2011 - The pharma giant Takeda Pharmaceutical is facing tens of thousands of lawsuits in the United States concerning allegations that its Actos diabetes drug can result in bladder cancer. With regulators deciding earlier this year that Actos, which has the chemical name of pioglitazone and is prescribed for adults with type 2 diabetes, could sometimes cause a heightened risk from cancer, judges are now assessing whether the various lawsuits should be consolidated.
READ MORE::
Takeda May Face 10,000 U.S. Suits Over Actos Cancer Claims
- Bloomberg
12/01/2011 - Takeda Pharmaceutical Co. (4502), Asia’s biggest drugmaker, may face as many as 10,000 lawsuits in U.S. courts over allegations that its Actos diabetes drug causes bladder cancer, and a group of judges is preparing to decide where they should be consolidated.
READ MORE::
FDA puts back decision on Takeda's new diabetes drugs
- Pharma Times
11/22/2011 - Takeda Pharmaceutical Co is going to have to wait a bit longer to get US approval for its type 2 diabetes therapy alogliptin, and the fixed-dose combination of the drug plus the Japanese drugmaker's Actos.
READ MORE::
Ennis & Ennis, P.A. Provides Update on Actos Litigation Cases
- Ennislaw
09/19/2011 - Plaintiffs, who have pending lawsuits against Japanese company Takeda Pharmaceuticals America Inc. (Takeda), the manufacturer of the Type II diabetes drug, Actos, filed a motion to transfer 11 pending actions, and all subsequent Actos injury actions, to a single judge for pretrial proceedings.
READ MORE::
Ennis & Ennis, P.A. Supports Petition to FDA to Revise Generic Drug Warning Label Regulations
- Ennislaw
08/31/2011 - Ennis & Ennis, P.A. strongly supports consumer advocacy group’s, Public Citizen, petition dated August 29, 2011 urging the U.S. Food and Drug Administration (FDA) to require manufacturers of generic drugs to promptly update warning labels when they learn of new side effects
READ MORE::
Ennis & Ennis, P.A. Announces Free, Nationwide, Confidential, Consultations for Actos Users
- Ennislaw
08/21/2011 - On August 4, 2011, the U.S. Food and Drug Administration (FDA) approved added warnings on the label of the Type II diabetes medication Actos, after reporting that its sole ingredient, pioglitazone, may increase the risk of bladder cancer (bladder tumors). According to Ennis & Ennis, P.A., the updated drug labels recommend that healthcare providers should not use pioglitazone in patients with active bladder cancer and should use pioglitazone with caution in patients with a prior history of bladder cancer. Pioglitazone is also sold as a combination drug under the names of Actoplus Met and Duetact.
READ MORE::
FDA Adds Bladder Cancer Risk Warning to Pioglitazone
- Family Practice News
08/08/2011 - The Food and Drug Administration said August 5 that it had approved new labels for the diabetes drug pioglitazone to include warnings about bladder cancer risk. The announcement follows the agency’s June 15 statement explaining its intention to craft new warnings on pioglitazone in light of interim findings from a 10-year epidemiologic study.
READ MORE::
Pioglitazone Gets New Cancer Risk Labeling
- Medpage Today
08/05/2011 - The FDA has approved updated label information for pioglitazone (Actos) and medications that contain it, following its warning in June about bladder cancer risk with the drug. The new labeling, released Friday, warns that use of pioglitazone for more than a year may increase the risk of bladder cancer, a finding based on an interim analysis of an epidemiological study.
READ MORE::
Diabetes Drug, Actos, May Lead to Bladder Cancer
- Ennislaw
08/01/2011 - On June 15, 2011, the U.S. Food and Drug Administration (FDA) required added warnings on the label of the diabetes medication, Actos (pioglitazone), which is manufactured by Takeda Pharmaceuticals, stating that it may increase the risk of bladder cancer when taken for more than one year, reports Ennis & Ennis, P.A. This warning came shortly after France and Germany suspended the use of pioglitazone.
READ MORE::
Takeda's Actos Pill Needs New Cancer-Risk Warning, Agency Says
- Bloomberg
07/26/2011 - Takeda Pharmaceutical Co.'s Actos diabetes drug may be kept on the market with new warnings, the European Medicines Agency said after reviewing research showing the drug carried a slightly increased risk of bladder cancer.
READ MORE::
EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk
- GEN
07/24/2011 - EMA is recommending that type 2 diabetes patients with current bladder cancer, a history of the disease, or uninvestigated macroscopic hematuria, should not be prescribed drugs containing Takeda’s Actos (pioglitazone). The recommendation follows a data review by the agency’s CHMP, which concluded that while pioglitazone-based medicines remain a valid treatment option for some patients with type 2 diabetes, the drug is associated with a small increased risk of bladder cancer.
READ MORE::
EU agency calls for new warnings on Takeda's Actos
- Reuters
07/21/2011 - Takeda Pharmaceutical's diabetes pill Actos should carry new warnings about its possible link to bladder cancer, Europe's drug regulator said on Thursday, following a safety review of the medicine.
READ MORE::
Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines regulator.
- InPharm
07/11/2011 - The Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) last month moved to prevent Actos (pioglitazone), and Takeda’s related brand Competact, from being prescribed by suspending their use. Now, with an EMA safety review still ongoing, AFSSAPS appears to have decided stronger local measures were necessary and asked for both drugs to be withdrawn altogether in France.
READ MORE::
Bristol-Myers, AstraZeneca Diabetes Drug Shows Bladder, Breast Cancer Risk
- Bloomberg
06/27/2011 - Bristol-Myers Squibb Co. and AstraZeneca Plc. said patients taking their experimental diabetes pill, shown effective in a two-year study, had more breast and bladder cancers than those on a standard drug. In all the clinical programs, nine breast cancers and nine bladder cancers were seen among 5,478 patients taking the drug, dapagliflozin, compared with one breast and one bladder cancer among the 3,156 in control groups, Bristol-Myers and AstraZeneca said in a statement today. There was no imbalance in overall cancer risk, the companies said.
READ MORE::
Longer-term use of Actos (pioglitazone) associated with an increased risk of bladder cancer
- Modern Medicine
06/22/2011 - FDA published an online safety communication on June 15, informing prescribers and patients that pioglitazone (Actos, Takeda Pharmaceuticals America Inc., Deerfield, Illinois) use may be associated with a 20% to 40% increased hazard of new bladder cancer.
READ MORE::
Diabetes Drug Actos May Raise Risk for Bladder Cancer: FDA
- US NEWS
06/18/2011 - The U.S. Food and Drug Administration is warning consumers that the popular diabetes drug Actos (pioglitazone) may increase the risk of bladder cancer when used for more than a year.
READ MORE::
Health Canada Reviewing Diabetes Drug Pioglitazone (Actos) and Potential Risk of Bladder Cancer
- Marketwire
06/18/2011 - In light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, Health Canada is informing healthcare professionals and Canadians that it is undertaking a review of the drug's status.
READ MORE::
Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
- PR News Wire
06/16/2011 - Following an announcement today from the U.S. Food and Drug Administration (FDA) regarding an update to its safety review of ACTOS, Takeda Pharmaceuticals North America, Inc. (Takeda) is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes. The company remains committed to ACTOS and ACTOS-containing medications, and to the millions of people living with the disease.
READ MORE::
FDA Warns of Bladder Cancer Risk With Actos
-ABC News Health
06/16/2011 - Patients taking the diabetes drug Actos for more than a year may have an increased risk of bladder cancer, according to an FDA interim review of an ongoing epidemiological study.
READ MORE::
Actos Side Effects Lawsuit:
If you have taken Actos and experienced serious Actos side effects such as Actos Bladder Cancer call our Actos lawyer today to find out about an Actos lawsuit. With offices in Washington D.C. and throughout Florida we are ready to help Actos side effects victims nationwide. Let our Actos Attorneys evaluate your case for free today. Fill out our online case evaluation form on this page or call us toll free at: 1.800.856.6405 for your free, confidential case evaluation.
Under no circumstances should you discontinue taking any medication, including Actos or Pioglitazone, without first consulting with your doctor.
Actos Bladder Cancer Side Effects Lawsuit Information:: |
